Post-Vaccination Surveillance of Invasive Pneumococcal Disease in Ghana
Diseases · 07.05.2026 · 14 (5) · 162
DOI: 10.3390/diseases14050162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases, online erschienen am 07.05.2026. Verfasst von Fleischer C N Kotey und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, Accra P.O. Box KB 4236, Ghana. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Pharmaceuticals, USA., Pfizer Pharmaceuticals, USA.
Abstract (Originalsprache)
Background
Streptococcus pneumoniae, also referred to as pneumococcus, is of immense public health significance. In particular, it causes severe invasive diseases among children. This has led to the recommendation of anti-pneumococcal prophylaxis, including the administration of penicillin and pneumococcal conjugate vaccines (PCVs), which have become available in about 90% of the countries in sub-Saharan Africa. Nonetheless, breakthrough disease still occurs. Also, PCVs can cause a shift in the distribution of pneumococcal serotypes, usually towards non-vaccine types. However, in many sub-Saharan African countries where PCVs have been introduced, there are hardly any comprehensive post-vaccination surveillance data on pneumococcus.
Aim
To describe the post-vaccination epidemiology of invasive pneumococcal disease (IPD) in Ghana, including the prevalence, serotype distribution and antibiotic resistance.
Methods
The study was cross-sectional and involved 14,597 patients recruited at the Korle Bu Teaching Hospital, Greater Accra Regional Hospital, Princess Marie Louise Children’s Hospital, Ho Regional Hospital, Eastern Regional Hospital, and Zonal Public Health and Reference Laboratory, Tamale. Specimens of cerebrospinal fluid (obtained by lumbar puncture) and blood were collected routinely from meningitis patients, while blood specimens were taken from pneumonia patients. These were cultured for S. pneumoniae following standard microbiological methods and subjected to antimicrobial susceptibility testing. The isolates were serotyped by the pneumotest latex agglutination kit, and the results confirmed by Quellung reaction, using serotype-specific antisera.
Results
The overall prevalence of IPD was 0.66% (n = 97), varying across syndromes: bloodstream infections (0.53%, n = 38), meningitis (2.45%, n = 43), and pneumonia (0.28%, n = 16). The majority of the cases (56.70%, n = 55) occurred in the 11–20-year-old group. Ten pneumococcal serotypes were identified, with Serotype 1 being predominant (58.76%), followed by Serotypes 23B (11.34%), 33F (9.28%), and 12F (8.24%). Vaccine serotypes accounted for 81.44% of the isolates, while 18.56% were non-vaccine serotypes (23A, 23B, and 38). Antimicrobial resistance was highest against sulphamethoxazole-trimethoprim (52%), ampicillin (51%), and penicillin (46%). No resistance was observed against ciprofloxacin, levofloxacin, and vancomycin. The multidrug resistance proportion was 42.3% (n = 41).
Conclusions
Even in the post-vaccination era, vaccine-type IPD remains a significant public health issue in Ghana. The observed serotype distribution and antimicrobial resistance patterns warrant sustained surveillance, more adaptive vaccination policies, and rigorous antibiotic stewardship to effectively mitigate IPD burden.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, Accra P.O. Box KB 4236, Ghana.
- Department of Science Laboratory Technology, Accra Technical University, Accra P.O. Box GP 561, Ghana.
- Greater Accra Regional Hospital, Accra P.O. Box 473, Ghana.
- Zonal Public Health and Reference Laboratory, Tamale P.O. Box TL 99, Ghana.
- Korle Bu Teaching Hospital, Korle Bu, Accra P.O. Box KB 77, Ghana.
- Eastern Regional Hospital, Koforidua P.O. Box KF 175, Ghana.
ORCID-Profile: Fleischer C N Kotey, Reuben E Arhin, Nicholas T K D Dayie, Francis K M Tetteh, Mary-Magdalene Osei, Patience B Tetteh-Quarcoo
Förderung
- Pfizer Pharmaceuticals, USA.
- Pfizer Pharmaceuticals, USA
Zitieren
APA
Kotey, F. C. N., Arhin, R. E., Dayie, N. T. K. D., Ampah, E. O., Abdul-Karim, A., Baah, D. A., Afful, R. M., Tetteh-Ocloo, G., Kom-Zuta, R. T., Tetteh, F. K. M., Osei, M. M., Brew, Y. N. A., Nyarko, M. Y., Asafo-Adjei, K., Tetteh-Quarcoo, P. B., Tette, E. M. A., & Donkor, E. S. (2026). Post-Vaccination Surveillance of Invasive Pneumococcal Disease in Ghana. Diseases, 14(5), 162. https://doi.org/10.3390/diseases14050162
Vancouver
Kotey FCN, Arhin RE, Dayie NTKD, Ampah EO, Abdul-Karim A, Baah DA, et al. Post-Vaccination Surveillance of Invasive Pneumococcal Disease in Ghana. Diseases. 2026;14(5):162. doi:10.3390/diseases14050162
BibTeX
@article{Kotey2026,
author = {Kotey, Fleischer C N and Arhin, Reuben E and Dayie, Nicholas T K D and Ampah, Emmanuel O and Abdul-Karim, Abass and Baah, Deric A and Afful, Ruth M and Tetteh-Ocloo, Georgina and Kom-Zuta, Roland T and Tetteh, Francis K M and Osei, Mary-Magdalene and Brew, Yvonne N A and Nyarko, Mame Y and Asafo-Adjei, Karikari and Tetteh-Quarcoo, Patience B and Tette, Edem M A and Donkor, Eric S},
title = {Post-Vaccination Surveillance of Invasive Pneumococcal Disease in Ghana},
journal = {Diseases},
year = {2026},
volume = {14},
number = {5},
pages = {162},
doi = {10.3390/diseases14050162}
}
EUVIMED